Press Release Details

Cerus Announces Proposed Public Offering of Common Stock

January, 05 2015

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Cerus also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover overallotments, if any. Cerus anticipates using the net proceeds from the offering for continued development activities related to the INTERCEPT Blood System, to fund commercialization efforts for the INTERCEPT Blood System in the United States and elsewhere, and for other general corporate purposes, including regulatory activity, selling, general and administrative expenses and working capital.

Cowen and Company, LLC and Robert W. Baird & Co. Incorporated are acting as joint book-running managers for the offering. Wedbush PacGrow Life Sciences and Stephens Inc. are acting as lead managers for the offering, and BTIG, LLC and MLV & Co. LLC are acting as co-managers for the offering.

The securities described above are being offered by Cerus pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or by calling 631-274-2806, or by faxing 631-254-7140; or from Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 E. Wisconsin Avenue, Milwaukee, Wisconsin 53202, by email at syndicate@rwbaird.com or by calling 800-792-2413.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, the INTERCEPT platelet and plasma systems have received FDA approval. The INTERCEPT red blood cell system is in clinical development.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to Cerus’ proposed public offering. These forward-looking statements are based upon Cerus’ current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks related to whether Cerus will be able to raise capital through the sale of shares of common stock, market conditions and the satisfaction of customary closing conditions related to the proposed public offering, risks related to the application of the net proceeds from the proposed public offering, risks associated with the uncertain research and product development process, and other risks detailed in Cerus' filings with the SEC, including in Cerus' quarterly report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 7, 2014 and in the preliminary prospectus supplement related to the proposed offering filed with the SEC on January 5, 2015. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

Source: Cerus Corporation

Cerus Corporation

Kevin D. Green, 925-288-6138

Vice President, Finance and Chief Financial Officer

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600